Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.56 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.56 |
| ▸ | CHKA | P35790 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP4 | P49662 | 1/20 | 0.50 |
| ▸ | CASP5 | P51878 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15309150 | 0.91 | KDM4E (0.64) | KDM4EALDH1A1HIF1AEPAS1CHKA | |
| SCHEMBL29586728 | 0.85 | KDM4E (0.89) | KDM4EALDH1A1HIF1AEPAS1CHKA | |
| SCHEMBL21620787 | 0.85 | ALDH1A1 (0.96) | KDM4EALDH1A1HIF1AEPAS1CHKA | |
| SCHEMBL13574523 | 0.83 | ALDH1A1 (1.00) | KDM4EALDH1A1HIF1AEPAS1CHKA | |
| SCHEMBL23864602 | 0.82 | ALDH1A1 (0.67) | KDM4EALDH1A1HIF1AEPAS1CHKA | |
| SCHEMBL978708 | 0.81 | KCNH2 (0.52) | KDM4EALDH1A1POLBSIGMAR1 | |
| SCHEMBL5316753 | 0.80 | MCHR1 (0.53) | — | |
| SCHEMBL12991443 | 0.80 | KDM4E (0.69) | KDM4EALDH1A1HIF1AEPAS1CHKA | |
| SCHEMBL2097422 | 0.80 | KDM4E (0.69) | KDM4EALDH1A1HIF1AEPAS1CHKA | |
| SCHEMBL16704827 | 0.80 | HIF1A (0.82) | KDM4EALDH1A1HIF1AEPAS1CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753749-B1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | claimed |
| CN-1980917-B | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2014-02-12 | — | — | CN | claimed |
| US-7282507-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-16 | — | — | US | claimed |
| CN-1980917-A | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | CN | claimed |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-03 | — | — | US | claimed |
| US-9434688-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| CN-105085358-A | 4-substituted pyrrolidine formyl thiomorpholine DPP-IV (Dipeptidyl Peptidase IV) inhibitor | INST MATERIA MEDICA CAMS | 2015-11-25 | — | — | CN | disclosed |
| EP-2078712-B1 | Indole derivatives as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-10 | — | — | EP | disclosed |
| CN-104211685-A | Thiomorpholine compounds containing substituted pyrrole alkyl groups | INST MATERIA MEDICA CAMS | 2014-12-17 | — | — | CN | disclosed |
| US-20140249197-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-09-04 | — | — | US | disclosed |
| EP-1753749-B1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-8765782-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-01 | — | — | US | disclosed |
| EP-1756109-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1753749-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005110985-A2 | INDOLE, BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111042-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111028-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | AR, NR5A1, FSHR | KDM4E 816/4885ALDH1A1 1696/4885HIF1A 1673/4885 |
| US-20140249197-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | KDM4E 1287/4885ALDH1A1 1333/4885HIF1A 1657/4885 |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | KDM4E 1287/4885ALDH1A1 1333/4885HIF1A 1657/4885 |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | AR, NR5A1, NR5A2 | KDM4E 1127/4885ALDH1A1 1274/4885HIF1A 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.